Barclays lowered the firm’s price target on Editas Medicine (EDIT) to $5 from $7 and keeps an Equal Weight rating on the shares. The company’s Q3 was incremental following the strategic update, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EDIT:
- Editas Medicine Reports Q3 2024 Results and Developments
- Editas Medicine price target lowered to $5 from $8 at RBC Capital
- Raymond James downgrades Editas on extended development timelines
- Editas Medicine downgraded to Market Perform from Outperform at Raymond James
- Editas Medicine reports Q3 EPS (75c), consensus (75c)